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Cancer‐related	 fatigue	 (CRF)	 is	 subjective	 and	has	wide	 inter‐individual	 variability.	
Given	that	leptin	is	commonly	associated	with	fatigue	syndrome,	its	use	as	a	potential	
biomarker	for	CRF	is	being	investigated.	The	primary	objective	of	this	study	was	to	
evaluate	 the	 association	between	 leptin	 and	CRF	 in	 early‐stage	breast	 cancer	 pa‐
tients	 receiving	 chemotherapy.	 In	 a	 prospective	 cohort	 study,	 patients	 completed	
assessments	at	baseline	(T1),	during	chemotherapy	(T2)	and	after	chemotherapy	(T3).	
Levels	of	plasma	leptin	and	adipokines	were	measured	using	a	Luminex	bead‐immu‐
noassay	 and	 CRF	 was	 measured	 using	 the	 Multi‐Dimensional	 Fatigue	 Symptom	
Inventory‐Short	Form	(MFSI‐SF).	Data	were	analysed	longitudinally	using	a	general‐
ised	 estimating	 equation	 incorporating	 clinically	 relevant	 parameters	 and	 
pro‐inflammatory	 adipokines.	 The	 analysis	 included	 136	 patients	 (mean	





total	MFSI‐SF	 score	 (β	=	−0.15,	P	=	0.003)	 after	 adjusting	 for	 the	 tumour	 necrosis	
factor‐α	 (TNF‐α)	 level,	 anxiety,	 depression,	 insomnia,	 age,	 menopausal	 status	 and	
type	of	chemotherapy.	This	is	the	first	study	to	report	leptin	as	a	biomarker	that	pre‐
dicts	 the	 onset	 of	 CRF	 over	 time.	 Future	 studies	 are	 required	 to	 validate	 the	
findings.
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1  | INTRODUC TION





tionate	 to	 recent	activity	and	 is	not	alleviated	by	 rest.2	 Left	unre‐
solved,	CRF	adds	on	to	patients’	distress	and	has	a	negative	impact	
on	their	quality	of	life.3
Given	 the	extent	of	 the	 impact	of	CRF	on	daily	 functioning,4 
addressing	 CRF	 should	 be	 an	 integral	 part	 of	 cancer‐supportive	
care.	 Nevertheless,	 this	 has	 proved	 challenging	 due	 to	 the	 lack	
of	an	objective	biomarker	to	monitor	these	symptoms.	The	expe‐




matory	 cytokines	 could	 be	 potentially	 employed	 as	 biomarkers	
of	CRF	in	patients	with	advanced	cancer,5	and	that	changes	from	
baseline	 of	 selected	 biomarkers	 were	 associated	 with	 changes	








to	 regulating	 body	 weight.7	 Leptin	 has	 shown	 moderate	 cor‐
relations	 to	 varying	 extents	 with	 fatigue	 in	 cohorts	 of	 patients	
with	 cardiovascular	 risk	 factors	 (r	=	0.22),8	 chronic	 fatigue	 syn‐
drome	(r	=	−0.51	to	0.73),6	chronic	hepatitis	C	infection	(r	=	0.25;	
r	=	0.30),9,10	and	irritable	bowel	syndrome	(r	=	0.60).11	In	another	
study,	 researchers	 found	 that	 plasma	 leptin	 levels	 could	 be	 in‐
duced	 by	 hydrocortisone,	 and	 were	 markedly	 increased	 in	 pa‐
tients	with	chronic	fatigue	syndrome.12	Hence,	we	hypothesized	






ipokines.	Our	primary	objective	was	 to	assess	 leptin's	potential	 to	
function	as	a	biomarker	that	could	predict	the	onset	of	CRF.
2  | MATERIAL S AND METHODS
2.1 | Study design
This	 prospective	 cohort	 study	was	 conducted	 between	 2014	 and	
2017	 in	 Singapore.	 The	 study	 was	 approved	 by	 the	 Singhealth	
Institutional	 Review	 Board	 (CIRB	 2014/754/B),	 and	 written	 in‐
formed	consent	was	obtained	from	all	study	participants.
2.2 | Inclusion and exclusion criteria











Patients	 were	 assessed	 at	 three	 time	 points:	 baseline	 before	
treatment	 initiation	 (T1),	 at	 least	 6	weeks	 after	 baseline	 during	











1.	 The	Multi‐dimensional	 Fatigue	 Symptom	 Inventory‐Short	 Form	
(MFSI‐SF)	 is	 questionnaire	 for	 measuring	 fatigue	 in	 cancer	 pa‐
tients.	 It	 consists	 of	 five	 subscales	with	 six	 items	each:	 general	
fatigue,	 physical	 fatigue,	 emotional	 fatigue,	 mental	 fatigue	 and	
vigour.	 Each	domain	 is	 rated	on	 a	 scale	 of	 0‐4.	 The	 total	 score	
is	 obtained	 by	 summing	 all	 the	 dimensions	 except	 the	 vigour	
domain	 which	 is	 subtracted.	 The	 total	 score	 ranges	 from	 −24	
to	96,	with	higher	scores	indicating	more	fatigue.	We	previously	
established	 the	 range	of	minimal	 clinically	 important	difference	
(MCID)	for	fatigue	worsening	as	4.50‐10.79.13	The	psychometric	
properties	 and	 measurement	 equivalence	 of	 the	 English	 and	
Chinese	versions	of	MFSI‐SF	have	been	demonstrated	in	breast	





gives	 a	 total	 score	 ranging	 from	 0	 to	 63,	 with	 a	 higher	 score	
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Quality	 of	 Life	 Questionnaire	 (EORTC	 QLQ‐C30)	 assesses	
HRQoL.	This	tool	was	used	for	the	assessment	of	insomnia	in	pa‐
tients,	with	a	higher	score	on	the	symptom	scale	indicating	greater	
severity.	 Both	 the	 English	 and	 Chinese	 versions	 had	 been	 vali‐
dated	for	use	in	cancer	patients.19,20
2.5 | Quantification of plasma pro‐inflammatory 















Patients’	 demographic	 information,	 clinical	 characteristics	 at	 base‐
line	and	the	proportions	of	patients	with	CRF	were	summarised	using	



























A	 total	 of	 136	 early‐stage	 breast	 cancer	 patients	 were	 included	
in	 this	 analysis,	 and	 their	 demographics	 are	 summarised	 in	
TA B L E  1  Baseline	demographics	and	clinical	characteristics	of	
patents	(n	=	136)
Demographic information
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3.3 | Plasma levels of adipokines and leptin across 
time points
The	 plasma	 levels	 of	 the	 individual	 adipokines	 are	 summarised	 as	
the	medians	with	the	interquartile	ranges	(Table	2).	There	were	sta‐
tistically	significant	changes	in	the	plasma	levels	of	leptin,	IL‐6,	Il‐8	




an	 increase	 in	 plasma	 levels	 towards	 the	 end	 of	 chemotherapy	 at	
T3	(T1:	0.80	pg/mL,	T2:	1.11	pg/mL,	T3:	1.27	pg/mL).	For	IL‐8,	there	
was	 a	 decrease	 in	 plasma	 levels	 at	 T2,	 followed	by	 an	 increase	 at	
TA B L E  2  Comparison	of	plasma	adipokine	and	leptin	levels	across	the	time	points
Biomarker
Plasma adipokine concentration in Median (Inter‐quartile 
range) Friedman Test
Post‐hoc analysis: Wilcoxon sign 
rank test
T1 T2 T3 P‐value T1‐T2 T1‐T3 T2‐T3
Leptin	(ng/mL)	 4.07	(2.96,	6.61)	 4.95	(3.27,	7.16)	 3.96	(2.68,	6.07)	 <0.001 <0.001 0.56 <0.001
IL‐6	(pg/mL)	 0.80	(0.36,	1.72)	 1.11	(0.57,	2.46)	 1.27	(0.53,	2.60)	 <0.001 <0.001 <0.001 0.07
IL‐8	(pg/mL)	 3.70	(2.29,	4.95)	 3.33	(2.25,	5.06)	 3.69	(2.48,	5.28)	 <0.001 0.42 0.04 <0.001





TA B L E  3  Correlation	of	plasma	adipokine	levels	and	known	confounders	against	leptin	at	individual	time	points	(T1,	T2	and	T3)
T1 T2 T3
r P‐value r P ‐value r P ‐value
IL‐6 0.14 0.18 0.07 0.50 0.07 0.52
IL‐8 0.20 0.02 0.06 0.46 0.06 0.46
TNF‐α −0.03 0.71 −0.07 0.44 −0.02 0.85
Anxiety −0.09 0.29 −0.03 0.70 0.008 0.92
Depression −0.20 0.02 −0.25 <0.001 −0.08 0.37
Insomnia −0.07 0.43 −0.02 0.83 −0.20 0.02
Body	mass	index 0.59 <0.001 0.56 <0.001 0.58 <0.001
Age 0.23 <0.001 0.15 0.08 0.16 0.07
Categorical variables
T1 T2 T3
z‐score P ‐value z‐score P ‐value z‐score P ‐value
Menopausal	status −3.14 0.002 −1.87 0.06 −2.51 0.01
Anaemia	status −0.54 0.59 2.34 0.02 −0.46 0.64
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T3	 (T1:	 3.70	pg/mL,	 T2:	 3.33	pg/mL,	 T3:	 3.69	pg/mL).	 For	 TNF‐α,	
there	was	a	sustained	increase	in	plasma	levels	(T1:	6.41	pg/mL,	T2:	
6.95	pg/mL,	T3:	8.27	pg/mL).
3.4 | Correlation of plasma adipokines levels and 
confounders against plasma leptin levels at individual 
time points
Considering	 relationships	 between	 leptin	 and	 each	 individual	 adi‐













3.5 | Correlation of plasma adipokines levels, known 
confounders and leptin against fatigue levels across 
time points (T1‐T3)
There	 were	 consistent	 strong	 correlations	 with	 fatigue	 levels	
across	 all	 time	points	 for	 anxiety,	 depression	 and	 insomnia.	Age	
was	 negatively	 correlated	with	CRF	 across	 time	 points	 and	CRF	




MFSI‐SF	 score	 (β =	−0.56,	P	<	0.001),	with	 every	 1	 unit	 decrease	
of	 leptin	 being	 associated	 with	 a	 0.56	 increase	 in	 total	MFSI‐SF	
score	(Table	2).	TNF‐α	was	also	inversely	correlated	with	the	total	




pression	 (β	=	1.85,	 P	<	0.001)	 and	 insomnia	 (β	=	0.15,	 P	<	0.001)	





3.6 | Adjusted model showing an association 
between leptin and CRF
Using	 P‐values	 <0.05	 as	 selection	 criteria,	 the	 variables	 with	 sta‐
tistically	 significant	 associations	 with	 CRF	 were	 TNF‐α,	 anxiety,	
depression,	 insomnia,	 age,	menopausal	 status	and	 type	of	 chemo‐
therapy.	 These	 variables	 were	 included	 as	 covariates	 in	 the	 final	
model.	 Results	 showed	 that	 leptin	 remained	 inversely	 associated	
with	 total	 MFSI‐SF	 score	 but	 the	 beta‐coefficient	 for	 leptin	 with	
the	MFSI‐score	was	attenuated	(β =	−0.15,	P	=	0.003),	with	every	1	
TA B L E  4  Correlation	of	plasma	adipokine	levels,	known	confounders	and	leptin	against	fatigue	levels	across	time	points	(T1‐T3)
T1 T2 T3 T1‐T3
r P‐value r P‐value r P‐value β (SE) P‐value
Leptin −0.25 0.005 −0.11 0.22 0.02 0.83 −0.56 (0.13) <0.001
IL‐6 0.007 0.94 0.17 0.10 0.09 0.36 0.50	(0.46)	 0.27
IL‐8 −0.07 0.45 −0.004 0.96 0.04 0.65 0.10	(0.38)	 0.12
TNF‐α 0.05 0.57 0.001 0.99 0.05 0.58 −0.02 (0.004) 0.003
Anxiety 0.65 <0.001 0.63 <0.001 0.68 <0.001 1.38 (0.13) <0.001
Depression 0.74 <0.001 0.74 <0.001 0.75 <0.001 1.85 (0.14) <0.001
Insomnia 0.30 <0.001 0.34 <0.001 0.44 <0.001 0.15 (0.03) <0.001
Body	mass	index −0.17 0.054 −0.05 0.59 −0.04 0.78 −0.39	(0.26)	 0.13
Age −0.34 <0.001 −0.27 0.002 −0.25 0.004 −0.57 (0.12) <0.001
Categorical variables
T1 T2 T3 T1‐T3
z‐score P‐value z‐score P‐value z‐score P‐value β (SE) P‐value
Menopausal	status 1.78 0.08 1.11 0.27 1.49 0.14 −5.59 (2.64) 0.04
Anaemia	status −0.73 0.47 −0.43 0.67 2.06 0.04 0.02	(0.01)	 0.09
Type	of	
chemotherapy
3.32 <0.001 3.57 <0.001 3.50 <0.001 −10.65 (2.32) <0.001
Abbreviation:	TNF‐α,	tumour	necrosis	factor‐α.
Bolded	are	p‐values	<	0.05.






respective	 five	 sub‐domains	 scores	 were	 not	 statistically	 signifi‐
cant	in	the	final	model	(Table	6).	In	the	analysis	of	other	explanatory	
variables	 in	 the	 final	 model,	 there	 were	 positive	 significant	 asso‐














fatigue‐associated	 processes	 in	 other	 disease	 states.	 The	 posi‐
tive	correlations	between	fatigue	and	adipokines	had	been	mostly	
observed	 in	 patients	 with	 other	 conditions	 marked	 by	 inflamma‐
tion.6,9,10	 For	 instance,	 in	 a	 cohort	 of	 patients	with	 cardiovascular	
risk	 factors,	 plasma	 leptin	 levels	 were	 significantly	 and	 positively	
associated	with	 fatigue	 score	 (r	=	0.22,	P	<	0.001)	 and	 retained	 an	
independent	 association	 in	 a	 multiple	 logistic	 regression.8	 Yet	 in	
another	 study	 evaluating	 patients	 with	 systemic	 lupus	 erythema‐
tosus,	there	was	no	significant	association	between	adipokines	and	
fatigue	levels,	but	their	correlation	was	reported	to	be	negative.	In	




ipokines	 and	 both	 physical	 activity	 and	 disease	 activity	 were	 ex‐
plained	by	differences	in	BMI.32















survivors,	 in	which	 the	 research	 team	reported	 that	patients	diag‐
nosed	with	 depression	 and	 anxiety	 before	 chemotherapy	were	 at	
higher	risk	of	fatigue	onset	at	a	later	period.3	This	finding	suggests	
that	some	psychological	symptoms	may	form	a	fairly	stable	symp‐
































Coefficient β (SE) P‐value
Constant 19.80 (3.39) <0.001
Adjusted	Leptin(ng/mL)	 −0.15 (0.05) 0.003
TNF−α(pg/mL)	 −0.009 (0.002) <0.001
Anxiety 0.74 (0.14) <0.001
Depression 1.06 (0.17) <0.001
Insomnia −0.002	(0.02)	 0.94
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Understanding	 the	 role	of	 leptin	 in	 relation	 to	CRF	may	help	
us	to	devise	more	tailored	 interventions	such	as	exercise	to	mit‐








tigue	 biomarker	 can	 have	 clinical	 utility.	 The	 observed	 difference	
in	direction	for	effect	of	leptin	on	fatigue	may	be	partly	attributed	
to	 the	non‐specific	 nature	of	 fatigue,	which	 can	be	 challenging	 to	
quantify	despite	use	of	validated	questionnaires	and	 is	dependent	






In	 conclusion,	 our	 data	 show	 that	 there	 is	 an	 inverse	 correla‐
tion	 between	 plasma	 leptin	 levels	 and	 fatigue	 levels	 over	 time	 in	
early‐stage	 breast	 cancer	 patients	 undergoing	 chemotherapy.	 The	
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